Ion Exchange (India) Ltd
Ion Exchange (India) Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
2 of 5 strong
The short version
The chemicals segment has a positive long-term outlook with continued investment and international market expansion, especially via the new Roha facility targeting exports. Engineering segment expected to benefit from healthy order book and project execution, including significant projects like the IOCL Panipat Refinery and Oman BOOT contract, ensuring revenue growth.
From Ion Exchange (India) Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The chemicals segment has a positive long-term outlook with continued investment and international market expansion, especially via the new Roha facility targeting exports.
- Roha plant aims for 25% capacity utilization in the first full year, with progressive customer acquisitions underway, supporting volume growth.
- Efforts are ongoing to grow revenues in the consumer products division, which increased 34% YoY, aiming to move towards breakeven or modest profitability.
- Engineering segment order book provides healthy revenue visibility, boosted by new medium-sized opportunities across sectors and international markets.
- The UP Jal Jeevan Mission and legacy projects will contribute revenue over the next financial year with expected execution ramp-up as government funding improves.
- The Oman BOOT contract will start contributing O&M revenue from this financial year, showing potential revenue growth in international operations.
- Despite short-term headwinds (West Asia crisis and input cost inflation), management expects sales and margin outlook to improve directionally in FY27.
Profitability & Margins
See what Ion Exchange (India) Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Roha Plant: Focus on utilizing existing Roha facility capacity with backward integration underway; no major new CAPEX planned immediately, only maintenance and routine CAPEX of Rs.30-40 crores for FY27.
- Oman Project: CAPEX of around USD 40 million over next two years planned, funded by a mix of debt and equity; Ion Exchange holds 51% in the JV.
- Strategic Investments: Partnership with MANN+HUMMEL to expand membrane technology portfolio for global markets.
- Future CAPEX: No major expansions currently envisaged; any new major CAPEX or plant expansion will be communicated later as plans crystallize.
- Debt Position: Gross debt expected around Rs.384 crores by end FY27 with CAPEX funded through internal accruals and partner contributions for JV projects.
Fundraising & Capital Structure
See what Ion Exchange (India) Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As of 31st March 2026, the engineering order book stood at INR 26,433 million, providing healthy revenue visibility going forward.
- The company’s order intake in the engineering segment has been quite healthy, with a 40% increase compared to the last full financial year.
- Major portion of the projects from this order book are expected to be executed in the current and next financial year.
- The backlog includes standalone orders only; joint venture orders such as those in Oman are excluded from reported backlog.
- The UP Jal Jeevan Mission project has around 30% of its scope pending execution, with execution pace dependent on government fund inflows.
- Legacy projects in the engineering segment are expected to complete by the second or third quarter of FY27, and the government has extended these timelines.
Ion Exchange (India) Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹863 Cr, net profit ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ion Exchange (India) Ltd's management said in earlier quarters
Others in Other Utilities this season
- Denta Water & Infra Solutions Ltd (Q4 FY26)
600 crores. Key concall takeaways from Denta Water & Infra Solutions Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
- Felix Industries Ltd (Q4 FY26)
Revenue from Operations showed strong growth, increasing by 178% from ₹36.82 crore (FY25) to ₹102.21 crore (FY26). Key concall takeaways from Felix Industries…
- Effwa Infra & Research Ltd (Q4 FY26)
As of end FY26, order book stands at around INR 750 crores. Key concall takeaways from Effwa Infra & Research Ltd's Q4 FY26 earnings call — and how it ranks…
- Antony Waste Handling Cell Ltd (Q4 FY26)
Growth driven by strong execution in collection & transportation (C&T) and processing segments, with C&T revenue up 11% and processing up 5% in FY26. Key…
Frequently Asked Questions
What were Ion Exchange (India) Ltd Q4 FY26 results?
The chemicals segment has a positive long-term outlook with continued investment and international market expansion, especially via the new Roha facility targeting exports. Engineering segment expected to benefit from healthy order book and project execution, including significant projects like the IOCL Panipat Refinery and Oman BOOT contract, ensuring revenue growth.
What is Ion Exchange (India) Ltd share price analysis?
Ion Exchange (India) Ltd currently shows a below-average growth signal. The stock trades at a P/E of 55.4 with a market cap of ₹6,097 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ion Exchange (India) Ltd planning capital expenditure?
Roha Plant: Focus on utilizing existing Roha facility capacity with backward integration underway; no major new CAPEX planned immediately, only maintenance and routine CAPEX of Rs.30-40 crores for FY27.
Keep Ion Exchange (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.